-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to stone pharmaceutical group public information, NBL-012 is a specific and efficient IL-23p19 antibody, can act on the upper reaches of the IL-23/IL-17 inflammatory path, inhibiting the differentiation of Th17 cells and the production of lelutin IL-17.
it is also an all-human IgG4 antibody with a lower risk of immunogenicity and adverse Fc-mediated tissue damage.
From the target point of view, the p19 sub-base (IL-23p19) of leukocyte interleukin 23 (IL-23) is the target for a variety of autoimmune diseases, including psoriasis, purulent sweat adenitis and inflammatory bowel disease, and has been clinically proven.
less than three years ago, NovaRock Biotherapeutics is a biotechnology company dedicated to the research and development of antibody therapies for cancer and autoimmune diseases.
NBL-012 is the first new antibody drug to enter the clinical stage in its own research and development pipeline.
the approved Phase 1 clinical trial will assess the safety, toerability and pharmacodynamic properties of the drug under study.
addition, NBL-015, another all-human anti-Cludin 18.2 monoclonal antibody recently developed by the company, was approved by the FDA as an orphan drug for the treatment of pancreatic cancer.
: Sing Pharmaceutical Group's new drug NBL-012 has been approved for clinical trials in the United States. Retrieved Jan 11, 2020, from
